TATFAR’s 2018 meeting: Live streaming of 7 Mar opening session

Dear All: On 7-9 Mar 2018, the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) will meet in Atlanta, GA to discuss:

  • Improving antibiotic use in humans and animals,
  • Preventing infections and their spread, and
  • Strengthening the drug pipeline.

The opening session (8.30-10.00a EST on 7 Mar) will be available for viewing via live-streaming

What is TATFAR? Created in 2009, TATFAR comprises AMR-focused government-level experts from Canada, the European Union (EU), Norway, and the United States. CDC maintains the secretariat for the group. TATFAR is currently working on implementation of a set of policy recommendations that span antibiotic use (human & veterinary), infection prevention, and strategies for improving the pipeline of new therapeutic options.

There’s no public agenda for the full meeting, but I infer that the focus is on reviewing progress to date and the need for any updates to TATFAR’s current policy recommendations. It’s great to see our government partners maintaining steady effort on the important problem of antimicrobial-resistant infections!

Why does a meeting of TATFAR matter? As a lot of the needed change requires government-level action, having a knowledgeable and engaged government-based effort is critical for any progress. No, we don’t yet have the drugs we need — but we do have a lot of push incentives, a growing pipeline of both traditional and non-traditional products, and a supportive regulatory environment. No, we don’t yet have pull incentives — but the recent DRIVE-AB reports plus the prior work of the UK AMR Review and the Duke-Margolis project on incentives are driving substantive conversations on both sides of the Atlantic.

In short, the very existence of this group is one of many positive signs in this space. I hope you can make time to dial-in to get a feel for what our government-based colleagues are doing. My own view is that the overall trajectory gives hope that we may yet have the tools needed for ourselves, our children, and our grandchildren.

Many thanks to all who engaged with making this happen! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top